版本:
中国

BRIEF-Intellia therapeutics announces European Patent Office's decision

April 11 Intellia Therapeutics Inc

* Intellia Therapeutics announces European Patent Office's decision to grant crispr/cas9 genome editing technology patent

* Intellia Therapeutics - patent covers compositions of crispr single guide RNA technology for use in non-cellular, cellular settings, including eukaryotic cells

* Intellia Therapeutics - EPO's decision to grant patent follows its March 24, notice of intent to issue patent, which was not challenged by any third party

* Intellia Therapeutics - European patent will cover, approximately forty European countries, including Germany, Italy, France, Spain and Netherlands Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐